Lonza Group Enters Drug Technology Deal with South Korea's Qurient

09:30 AM EDT, 10/12/2026 (MT Newswires) -- Lonza Group (LONN.SW) and South Korean biopharmaceutical company Qurient signed an exclusive dual-payload platform licensing agreement, according to a Monday release. The deal allows the Swiss healthcare-focused manufacturing company to use Qurient's cyclin-dependent kinase 7, or CDK7, inhibitors for dual-payload antibody-drug conjugate applications targeting cancer.